Basel-based NUCLIDIUM, a clinical-stage radiopharmaceutical firm creating a proprietary copper-based theranostic platform, immediately introduced the profitable closing of its Collection B financing spherical, elevating €84 million.
The spherical was led by Kurma Development Alternatives Fund, Angelini Ventures, Wellington Companions, and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech & Local weather Fonds (DTCF), Bayern Kapital, Vives Companions, Eurazeo, NRW.BANK and HighLight Capital, in addition to current traders.
“NUCLIDIUM is getting into the subsequent medical phases with its lead compounds to diagnose and deal with metastatic prostate, neuroendocrine tumors and breast most cancers,” mentioned Leila Jaafar, PhD, CEO and Co-Founding father of NUCLIDIUM. “Our copper-based radiotheranostics are developed for seamless use in hospital workflows, care supply and waste administration, making these therapies extra accessible worldwide. Our groundbreaking subsequent era copper theranostic platform additionally permits us to quickly develop new targets throughout a wider vary of cancers, notably these extremely related to ladies’s well being.”
Based in 2017, NUCLIDIUM AG is a clinical-stage BioTech firm innovating the event of next-generation copper-based radiopharmaceuticals for the prognosis and remedy of most cancers.
Leveraging copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – NUCLIDIUM is making a differentiated platform with the potential to beat current limitations in radiotheranostics.
NUCLIDIUM says they’re dedicated to increasing the attain and efficacy of radiotheranostics, together with addressing crucial unmet medical wants in oncology and girls’s well being.
NUCLIDIUM’s differentiated platform hyperlinks tumor-targeting molecules with copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – to deal with present limitations in radiotheranostics, equivalent to suboptimal medical efficacy and complicated manufacturing.
“VIVES Companions is thrilled to be among the many contributors on this vital fundraising spherical,” mentioned Sandra Schoors, companion at VIVES Companions. “We’ve a robust perception within the potential of Nuclidium’s copper-based platform as a novel radiotheranostic. The corporate’s progressive strategy tackles the crucial limitations in present radiopharmaceutical strategies, paving the best way for more practical and accessible most cancers therapies. We’re excited to help this groundbreaking know-how and stay up for its transformative impression on healthcare.”
Diagnostic outcomes from preliminary medical trials in these indications present superior lesion detection and better tumor-to-background ratios in contrast with clinically authorized tracers. Initial data were recently presented at SNMMI 2025 by Dr Gary Ulaner, MD, PhD highlighting a positive security profile and doubtlessly improved imaging efficiency of 61Cu-NuriPro™ in comparison with present PET imaging requirements, suggesting sturdy medical promise and broader potential for 61Cu/67Cu theranostic pairing.
Early therapeutic knowledge from the 2 lead compounds, NuriPro™ and TraceNET™, reportedly present sturdy tumor-to-background ratios in metastatic prostate most cancers and neuroendocrine tumors together with breast most cancers.
“This vital Collection B financing displays the arrogance of our traders in NUCLIDIUM’s imaginative and prescient and the transformative potential for the diagnostic and therapeutic business in oncology and nuclear drugs,” mentioned Tony Rosenberg, Chairman of the NUCLIDIUM Board. “With this backing, we’re positioned to speed up medical growth, broaden affected person entry globally, and reinforce our dedication to innovation in precision oncology. I’m delighted to welcome our new Board and advisory members, whose deep experience will additional strengthen NUCLIDIUM’s management in radiopharmaceuticals.”
With this financing, NUCLIDIUM will proceed increasing its worldwide manufacturing and manufacturing community for diagnostics and therapeutics, rising its worldwide staff, and strengthening strategic collaborations with hospitals and tutorial centres, initially throughout Europe and North America.
The proceeds may even be used to advance the medical growth of NUCLIDIUM’s Copper-61/Copper-67 (61Cu/67Cu) theranostic pipeline throughout a number of oncology indications.
Together with the financing spherical, Daniel Parera, MD, Accomplice at Kurma Companions, Regina Hodits, PhD, Managing Director at Angelini Ventures, and Liliana Nordbakk, Accomplice Life Sciences at Neva SGR, will be a part of NUCLIDIUM’s Board of Administrators.
“NUCLIDIUM’s platform stands out in a quickly evolving area and can change how radiotheranostic care is delivered. This funding displays our sturdy conviction in the way forward for precision drugs and our perception in NUCLIDIUM’s potential to scale as a next-generation firm – an ambition shared throughout a robust European syndicate,” added Daniel Parera, MD, Accomplice at Kurma Companions, Regina Hodits, PhD, Managing Director at Angelini Ventures, and Liliana Nordbakk, Accomplice Life Sciences at Neva SGR for all taking part traders.
